目的 探討鋁鎂加混懸液聯(lián)合伏諾拉生治療反流性食管炎的臨床療效。方法 選取2019年3月—2021年3月空軍軍醫(yī)大學第二附屬醫(yī)院消化內(nèi)科收治的120例反流性食管炎患者，按照隨機數(shù)字表法將所有患者分為對照組和治療組，每組各60例。對照組口服富馬酸伏諾拉生片，20 mg/次，1次/d。治療組在對照組基礎上口服鋁鎂加混懸液，1袋/次，4次/d。兩組用藥7周。觀察兩組的治療效果，比較兩組癥狀緩解時間、血清胃激素水平、血清炎性因子水平。結果 治療后，治療組總有效率是98.33%，顯著高于對照組的83.33%（P＜0.05）。治療后，治療組反酸、燒心、胸痛、噯氣等癥狀緩解時間均短于對照組（P＜0.05）。治療后，兩組胃蛋白酶I（PGI）、胃動素（GAS）、胃泌素（MOT）水平均較治療前顯著降低（P＜0.05）；治療后，治療組PGI、GAS、MOT水平均低于對照組（P＜0.05）。治療后，兩組白細胞介素-1β（IL-1β）、白細胞介素-2（IL-2）、腫瘤壞死因子-α（TNF-α）、白細胞介素-17（IL-17）水平均較治療前顯著降低（P＜0.05）；治療后，治療組血清學指標水平低于對照組（P＜0.05）。結論 鋁鎂加混懸液聯(lián)合伏諾拉生治療反流性食管炎效果確切，可較好地緩解相關臨床癥狀，并能有效降低機體炎性反應，值得推廣使用。

Objective To investigate the clinical study of Almagate Suspension combined with vonoprazan in treatment of reflux esophagitis.Methods A total of 120 patients with reflux esophagitis admitted to the Department of Gastroenterology of the Second Affiliated Hospital of Air Force Medical University from March 2019 to March 2021 were selected.All patients were divided into control group and treatment group according to the random number table method,with 60 cases in each group.Patients in the control group were po administered with Vonoprazan Fumarate Tablets,20 mg/time,once daily.Patients in the treatment group were po administered with Almagate Suspension on the basis of the control group,1 bag/time,4 times daily.Both groups were treated for 7 weeks.The treatment effect of the two groups was observed,and the symptom relief time,serum gastric hormone level and serum inflammatory factor level were compared between the two groups.Results After treatment,the total effective rate of the treatment group was 98.33%,which was significantly higher than 83.33% of the control group (P<0.05).After treatment,the remission time of acid regurgitation,heartburn,chest pain,belching and other symptoms in the treatment group were shorter than those in the control group (P<0.05).After treatment,the levels of pepsin I (PGI),motilin (GAS) and gastrin (MOT) in the two groups were significantly decreased compared with those before treatment (P<0.05).After treatment,the levels of PGI,GAS and MOT in the treatment group were lower than those in the control group (P<0.05).After treatment,the levels of interleukin-1β(IL-1β),interleukin-2(IL-2),tumor necrosis factor-α(TNF-α) and interleukin-17(IL-17) in the two groups were significantly decreased compared with those before treatment (P<0.05).After treatment,the serum level of the treatment group was lower than that of the control group (P <0.05).Conclusion Almagate Suspension combined with vonoprazan has exact effect in treatment of reflux esophagitis,and can relieve the related clinical symptoms and effectively reduce the inflammatory response of the body,which is worthy of popularization and use.

R975

陜西省科技惠民計劃項目(2015HM-11)